Do local investors make a difference?

Do local investors make a difference?

E-mail outreach, online meetings and digital data rooms have become a given when trying to finance a therapeutic innovation! So, do local or regional anchor investors matter when developing a bioinnovation ecosystem? If the local innovation is world class, would it then not attract capital from wherever available?

Sunstone, in collaboration with our local peers and as a Nordic based investor, claims to play an important role in finding, developing and financing biotherapeutic opportunities that end up attracting international investors. But do we have data  to support that claim? or should politicians and sovereign funds not care about supporting local investors – and just focus on the quality of local/regional innovation?

To understand the impact of local investors Sunstone studied Danish companies having received financings from 2010 and forward. We looked at the HQ address of the VC’s participating in Seed, Series A and subsequent rounds in Denmark. The figure below illustrates how the geographical distribution of investors changes as Danish therapeutic companies progress in financing. The 1st bar illustrates the geographic distribution of investors in Seed investments that by now are unlikely to achieve a Series A (have been trying for +4 years), the second bar shows the companies that we assume are still able to achieve a series A and the third bar the companies that actually managed to get a series A financing. The data should be interpreted with caution as it covers more than 15 years of trends in investor behavior. Nevertheless, it indicates that local investors increase the likelihood of achieving a later series A – when comparing the 1st and 3rd bar. The 4th and 5th bar illustrate how the geographical mix of investors evolve in Series A and later financings. If on average, investors invest the same amount in a financing, the data suggests that local investors play an important role in seeding companies and need to support approximately 50% of series A investments to progress local or regional innovation.

What are your thoughts? – How important are the local or regional investors to the innovation ecosystem?

What do you think?
Let us know in our feed on LinkedIn:

5 latest press releases

Treetop Meeting

We usually do not share updates from internal meetings - but this was too fantastic not to share. A full day meeting in the midst of branches of +100 year old oaks and beech trees overlooking Isefjorden in “the treetop huts” at Ryegaard & Trudsholm Godser. Spiced...

Hans T. Scambye joins Sunstone as Venture Partner

Sunstone is delighted to announce that experienced biotech executive and CEO of Galecto Hans T. Schambye will be joining our team as new Venture Partner as of 1st February 2025. With a background as an MD and PhD Hans brings to Sunstone over 25 years of experience...

Neumirna Therapeutics secures euro 20M in Series A financing

Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the first closing of its Series A funding round at €20M. The investment was co-led by new investors, Angelini...

Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that liver imaging drug candidate, Orviglance®, significantly improved visualization of focal liver lesions, successfully...

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk

Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of...

5 latest articles

Is biotech venture capital investing more to return less?

At Sunstone we continue to track risk-adjusted return multiples (adjusted for contingent payments) versus the total capital invested in private therapeutic companies prior to M&A exits. When looking at the median trends over the past 15 years, the inflection...

An update on M&A returns for biotech venture capital

Back in in 2019 Sunstone started sharing studies of European venture capital funded successes – i.e. M&A transactions. In 2021 we started adding US M&A’s to the data and later the same year we evaluated to which extent an IPO impacted the observations made....

Biotech ecosystem contributors!

Biotech ecosystem contributors! In our previous post, we discussed the importance of local investors and how, in a Danish context, they contribute to identifying and scaling local and regional therapeutic innovation. However, not all investors are born equal - and an...

Seed & Series A in Denmark

Financing a Danish Biotech company has apparently never been more challenging. Based on feedback from partnering meetings in 2025 it seems that raising Series A financing has become an unprecedented challenge. However, when looking at the available data on the...

The 10 Advisements

We have the utmost respect for the courage, dedication, and resilience it takes to be an entrepreneur in our industry - especially when you’re out raising your next round of financing. That’s why we’ve decided to share our “10 Advisements” for crafting a compelling...

Saving Lives with Venture Capital

In 2023 we posted our thoughts on how to calculate the potential lifesaving impact of biotech venture capital (https://bit.ly/3z4mL0o) – and we promised to expand on the topic. Unfortunately, or rather fortunately, we got busy making investments in DioGenX, Kynexis...